

**Roundtable Meeting
with
Secretary - US Department of Health and Human Services**

Indian Pharmaceutical Industry

**by
D G Shah
Secretary General
Indian Pharmaceutical Alliance**

**Mumbai
15 January 2012**

About IPA

Focus Areas

- IPR Regime to Serve National Interest
- Drug Regulatory Framework
- Balanced Pricing Regime
- Non-tariff Barriers to Exports
- Counterfeit Medicines


Strengths

- 80% of Private Sector R&D Spend
- 40% of Exports
- 33% of Domestic Market

Indian Pharmaceutical Industry

Domestic Sales

Bn \$




Source IMS Health

Indian Pharmaceutical Industry

Bn \$

Export Sales




Source CMIE: Economic Intelligence Service (EIS)

Indian Pharmaceutical Industry

Countries	2009-10	Contrn
	Mn \$	%
USA	2,027	21.7
UK	364	3.9
Germany	334	3.6
Russia	289	3.1
South Africa	259	2.8
Brazil	220	2.3
Nigeria	201	2.1
Canada	171	1.8
Viet Nam	157	1.7
Netherlands	152	1.6
Turkey	147	1.6
China	144	1.5
Italy	132	1.4
UAE	129	1.4
Thailand	128	1.4
Ukrain	127	1.4
Spain	126	1.3
Kenya	123	1.3
Iran	119	1.3
Other	4,007	42.8
Total	9,354	100

Major Export Destinations




Source: Pharmexil

Pharmacy of the World

Indian Pharmaceutical Industry


Country-wise Active DMFs with US FDA - 2008



Source: Research based on CDER, US FDA database

Indian Pharmaceutical Industry

Year-wise ANDAs Approved from India: 1998-2008



Source: Research based on US FDA Orange Book & drug@fda

IPA Campaign Against Counterfeit Medicines

Summary of Actions – Punjab, UP and Delhi

January to December 2010

Sr. No.	Team	No. Of Raids	Value of Goods Seized Rs/Lakhs	No of Person Arrested
1	Punjab	28	24.81	08
2	UP	73	495.00	70
3	Delhi*	19	168.00	16
	Total:	120	687.81	94

* Report for April to September 2009

The Only Association Actively Campaigning Against Counterfeit Medicines



THANK YOU

dgshah@vision-india.com